US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Johnson & Johnson (NY:JNJ)

256.03 -2.63 (-1.02%)
Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
These dow jones stocks are moving in today's session ↗
Via Chartmill
What's going on in today's session: dow jones movers ↗
Via Chartmill
Johnson & Johnson (NYSE:JNJ) Is a Top Dividend Quality Stock for Reliable Income ↗
Via Chartmill
News headline image
FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System ↗
FDA grants De Novo authorization for Johnson & Johnson's OTTAVA robotic surgical system for general surgery procedures. 
Via Benzinga
These dow jones stocks are moving in today's session ↗
Via Chartmill
Johnson & Johnson (NYSE:JNJ) Raises Full-Year Guidance After In-Line Q2 Results ↗
Via Chartmill
News headline image
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
From Johnson & Johnson
Via Business Wire
Which dow jones stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Stay informed with the top movers within the dow jones index on Monday. ↗
Via Chartmill
News headline image
5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama ↗
While AI stocks correct, Johnson & Johnson, Altria, Coca-Cola, JPMorgan, and Apple are quietly trading near 52-week or all-time highs ahead of earnings. 
Via MarketBeat
Topics Artificial Intelligence Initial Public Offering
News headline image
PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗
PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report? ↗
J&J has more than 28 sources of blockbuster revenue. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
My 2 Favorite Dividend Kings to Buy Right Now ↗
They can help stabilize your portfolio in these otherwise volatile times. 
Via The Motley Fool
Topics Intellectual Property
News headline image
MarketBeat Week in Review – 07/13- 07/17 ↗
A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings. 
Via MarketBeat
Topics Artificial Intelligence Economy Stocks
These dow jones stocks are moving in today's session ↗
Via Chartmill
Top dow jones movers in Friday's session ↗
Via Chartmill
News headline image
Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst ↗
The reasons why RBC Capital Markets maintains its stock rating. 
Via Benzinga
News headline image
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? ↗
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage. 
Via The Motley Fool
News headline image
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? ↗
IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles. 
Via The Motley Fool
Topics ETFs
News headline image
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
From Johnson & Johnson
Via Business Wire
News headline image
DePuy Synthes Acquires Expanding Innovations™
From DePuy Synthes
Via Business Wire
News headline image
Full Transcript: Johnson & Johnson Q2 2026 Earnings Call ↗
Johnson & Johnson (NYSE:JNJ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For... 
Via Benzinga
News headline image
Is Johnson & Johnson a Buy After Its Latest Earnings Report? ↗
Investors didn't seem to think so after the company published it. 
Via The Motley Fool
News headline image
Author’s Tranquility Press Announces a Powerful New Memoir of Faith, Survival, and Purpose
Via AB Newswire
What's going on in today's session: dow jones movers ↗
Via Chartmill
News headline image
Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity ↗
Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch. 
Via MarketBeat
Topics Intellectual Property
Stay informed with the top movers within the dow jones index on Wednesday. ↗
Via Chartmill
News headline image
Johnson & Johnson Q2 Earnings Call Highlights ↗
Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook ↗
Johnson & Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and MedTech. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >